Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

Advanced or recurrent mucinous carcinoma of the ovary minimally responds to current cytotoxic treatments and has a poor prognosis. Despite multimodal treatment with chemotherapy and surgery, most patients ultimately progress and require palliative systemic therapy. Anti-HER2 therapy has been demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Xiangming, Mou, Haibo, Ying, Xinxin, Hou, Xuehua, Wang, Luo, Wu, Ying, Yan, Naimeng, Guo, Lijie, Liao, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815494/
https://www.ncbi.nlm.nih.gov/pubmed/36620566
http://dx.doi.org/10.3389/fonc.2022.1024677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815494/
https://www.ncbi.nlm.nih.gov/pubmed/36620566
http://dx.doi.org/10.3389/fonc.2022.1024677

Ejemplares similares